Rescue Hearing
Rescue Hearing Inc. is dedicated to revolutionizing the treatment of hearing loss through innovative gene therapies. With a focus on genetic causes of hearing impairment, the company develops targeted, life-changing solutions leveraging advanced biotechnology, gene therapy, and diagnostics. Their mission is to eliminate hearing loss as a chronic condition and restore hearing function worldwide, driven by a passionate team of physicians, scientists, and industry experts. They are actively engaged in research, clinical trials, and strategic partnerships to bring groundbreaking therapies to market, aiming to transform lives and redefine hearing care.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Gene therapy candidate — DFNB8 (post-lingual deafness)
Pipeline program focused on a genetic form of post-lingual deafness commonly observed in cochlear implant populations.
Gene therapy candidate — USH1B (Usher syndrome, vestibular disorders)
Program addressing auditory and vestibular dysfunction associated with Usher syndrome type 1B, with a focus on restoring vestibular function and hearing.
Gene therapy candidate — DFNB16 / STRC (STRC-associated hearing loss)
Program targeting STRC-related hearing loss (DFNB16), a form of genetic hearing impairment where hair cells remain intact and may be amenable to gene replacement strategies.
Gene therapy candidate — DFNB77 (nonsyndromic hearing loss)
Pipeline program addressing a nonsyndromic genetic form of hearing loss observed in the cochlear implant population.
Neurotrophic disorders program (inner ear cell targets)
Programmatic effort to apply gene therapy approaches to neurotrophic and inner-ear cell targets to preserve or restore auditory function.
Gene therapy candidate — DFNB8 (post-lingual deafness)
Pipeline program focused on a genetic form of post-lingual deafness commonly observed in cochlear implant populations.
Gene therapy candidate — USH1B (Usher syndrome, vestibular disorders)
Program addressing auditory and vestibular dysfunction associated with Usher syndrome type 1B, with a focus on restoring vestibular function and hearing.
Gene therapy candidate — DFNB16 / STRC (STRC-associated hearing loss)
Program targeting STRC-related hearing loss (DFNB16), a form of genetic hearing impairment where hair cells remain intact and may be amenable to gene replacement strategies.
Gene therapy candidate — DFNB77 (nonsyndromic hearing loss)
Pipeline program addressing a nonsyndromic genetic form of hearing loss observed in the cochlear implant population.
Neurotrophic disorders program (inner ear cell targets)
Programmatic effort to apply gene therapy approaches to neurotrophic and inner-ear cell targets to preserve or restore auditory function.
Services
Negotiation and management of exclusive licensing agreements and strategic partnerships to advance gene therapy candidates toward clinical development.
Execution of cell-based and in vivo proof-of-concept studies to evaluate gene therapy candidates and mechanisms prior to regulatory filing.
Design and management of patient data collection and natural history studies to inform endpoint selection and regulatory strategy.
Provision of informational content, guidance on genetic testing, and community resources for patients and families affected by hearing loss.
Negotiation and management of exclusive licensing agreements and strategic partnerships to advance gene therapy candidates toward clinical development.
Execution of cell-based and in vivo proof-of-concept studies to evaluate gene therapy candidates and mechanisms prior to regulatory filing.
Design and management of patient data collection and natural history studies to inform endpoint selection and regulatory strategy.
Provision of informational content, guidance on genetic testing, and community resources for patients and families affected by hearing loss.
Expertise Areas
- Gene therapy development for auditory disorders
- AAV vector design and manufacture
- Preclinical development and animal models
- Natural history studies and clinical trial design
Key Technologies
- AAV vectors
- CRISPR/Cas9 gene editing
- Dual-vector delivery approaches
- Molecular imaging
News & Updates
Rescue Hearing Inc. (RHI) partners with Myrtelle to accelerate gene therapy solutions for hearing loss.
Rescue Hearing Inc. announces the appointment of Dr. Athanasia Warnecke to its Scientific Advisory Board.
Rescue Hearing Inc. reaches milestone with a novel gene therapy technique for STRC gene-related hearing loss.
Rescue Hearing Inc. announces presentation of research findings at the ARO MidWinter Meeting.
Rescue Hearing Inc. adds business advisor to its team.
Rescue Hearing Inc. welcomes new drug development advisor.
Rescue Hearing Inc. (RHI) partners with Myrtelle to accelerate gene therapy solutions for hearing loss.
Rescue Hearing Inc. announces the appointment of Dr. Athanasia Warnecke to its Scientific Advisory Board.
Rescue Hearing Inc. reaches milestone with a novel gene therapy technique for STRC gene-related hearing loss.
Rescue Hearing Inc. announces presentation of research findings at the ARO MidWinter Meeting.
Rescue Hearing Inc. adds business advisor to its team.
Rescue Hearing Inc. welcomes new drug development advisor.